Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.4K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.2K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.2K
Bacterial Transformation01:33

Bacterial Transformation

60.4K
In 1928, bacteriologist Frederick Griffith worked on a vaccine for pneumonia, which is caused by Streptococcus pneumoniae bacteria. Griffith studied two pneumonia strains in mice: one pathogenic and one non-pathogenic. Only the pathogenic strain killed host mice.
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
60.4K
Metal-Ligand Bonds02:51

Metal-Ligand Bonds

24.5K
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
24.5K
Qualitative Analysis03:46

Qualitative Analysis

25.2K
For solutions containing mixtures of different cations, the identity of each cation can be determined by qualitative analysis. This technique involves a series of selective precipitations with different chemical reagents, each reaction producing a characteristic precipitate for a specific group of cations. Metal ions within a group are further separated by varying the pH, heating the mixture to redissolve a precipitate, or adding other reagents to form complex ions.
For instance, group IV...
25.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical impact of genetic testing in inherited kidney diseases.

Clinical kidney journal·2026
Same author

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
Same author

German Clinical Practice Guideline on Microhematuria in Children and Young Adults: Evaluating Early Detection of Kidney Disease.

Kidney international reports·2026
Same author

Monoallelic and biallelic KDM5A variants identified in patients with autism spectrum disorder.

HGG advances·2026
Same author

Severe systemic lupus erythematosus with thrombotic microangiopathy: rescue therapy with pegcetacoplan.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Late Onset of Congenital TTP: Case Presentation and Review of the Literature.

Clinical medicine insights. Case reports·2026
Same journal

KDIGO stage 3 acute kidney injury in children with severe Plasmodium falciparum malaria including blackwater fever: a case series from a resource-limited setting in Southwest Ethiopia.

BMC nephrology·2026
Same journal

Retraction Note: Trends in chronic kidney disease mortality among patients with systemic lupus erythematosus: a U.S. population-based study (1999-2020).

BMC nephrology·2026
Same journal

Biopsy-confirmed Mycobacterium kansasii peritonitis with CT peritoneography in a young PD patient: a case report.

BMC nephrology·2026
Same journal

Histoplasmosis in kidney transplant recipients.

BMC nephrology·2026
Same journal

Severe metabolic acidosis with renal tubular acidosis features attributed to topical brinzolamide in a patient with stage 3 chronic kidney disease: a case report.

BMC nephrology·2026
Same journal

Spatial transcriptomic profiling reveals molecular signatures of endocapillary hypercellularity in IgA nephropathy.

BMC nephrology·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K

Treating C3 glomerulopathy with eculizumab.

Thomas Welte1, Frederic Arnold1, Julia Kappes2

  • 1Department of Nephrology, Medical Center-University of Freiburg, Germany, Hugstetter Strasse 55, 79106, Freiburg, Germany.

BMC Nephrology
|January 14, 2018
PubMed
Summary
This summary is machine-generated.

Eculizumab may benefit some C3 glomerulopathy (C3G) patients, but responses vary. Early and continuous treatment is key, and identifying genetic factors could predict eculizumab effectiveness in this rare kidney disease.

Keywords:
C3 glomerulonephritisC3 glomerulopathyComplementDense deposit diseaseEculizumab

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K
Preparation of 2-dGuo-Treated Thymus Organ Cultures
07:50

Preparation of 2-dGuo-Treated Thymus Organ Cultures

Published on: August 28, 2008

15.1K

Related Experiment Videos

Last Updated: Feb 15, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.4K
Preparation of 2-dGuo-Treated Thymus Organ Cultures
07:50

Preparation of 2-dGuo-Treated Thymus Organ Cultures

Published on: August 28, 2008

15.1K

Area of Science:

  • Nephrology
  • Complement System Biology
  • Rare Diseases

Background:

  • C3 glomerulopathy (C3G) is a severe kidney disease with poor prognosis.
  • Its pathogenesis involves dysregulation of the complement cascade's alternative pathway.
  • Currently, no definitive therapies exist for C3G.

Purpose of the Study:

  • To evaluate eculizumab as a treatment for C3G.
  • To identify parameters predicting treatment response in C3G patients.

Main Methods:

  • Seven C3G patients (5 C3 glomerulonephritis, 2 dense deposit disease) received eculizumab.
  • Histopathology, clinical data, and treatment response were analyzed.
  • Changes in serum creatinine and urinary protein determined outcomes.

Main Results:

  • Four patients showed improved or stable renal function and proteinuria.
  • Positive responses occurred within 2 weeks to 6 months.
  • One patient relapsed after discontinuation; two showed no improvement.

Conclusions:

  • Eculizumab may be a viable option for a subset of C3G patients.
  • Treatment response is heterogeneous, necessitating early and continuous therapy.
  • Further research is needed to identify genetic factors for predicting eculizumab response.